Gene Therapy Market Research Reports & Industry Analysis
Gene Therapy Industry Research & Market Reports
-
Stem Cell and Gene Threapy Biological Testing Market, Size, Share, Outlook and Growth Opportunities 2019-2025
... Threapy Biological Testing markets and companies with emphasis on market size, growth factors, R&D investments, market shares and 2019 market dynamics. The report is structured to understand the key strategies of Stem Cell and Gene ... Read More
-
Gene Amplification Technologies Market by Application and Geography - Global Forecast and Analysis 2019-2023
... forensic and identity testing, agricultural and food safety, and other applications. Our analysis also considers the sales of gene amplification technologies in Asia, Europe, North America, and ROW. In 2018, the medical and pharmaceutical segment ... Read More
-
Gene Therapy Market - Growth, Trends, and Forecast (2019 - 2024)
... the market growth includes rising investments in the R&D, technological advancements, and growing prevalence of target diseases. Gene therapy is no longer considered a futuristic dream and instead, it has become a treatment for the ... Read More
-
Gene Therapy Market (3rd Edition), 2019 - 2030
... Zynteglo™ (Europe) and Collategene® (Japan), have received approval / conditional approval, leading to a marked upward surge in the interest in this field. In fact, the growing popularity can be correlated to the substantial increase ... Read More
-
Global Market for Gene Therapy 2019 – Product Pipeline, Market Size, & Forecasts
... faulty or missing genes in order to treat genetic diseases. This report reviews key developments from across the gene therapy sector, evaluating the industry’s commercial successes and failures, regulatory issues across key global markets, manufacturing ... Read More
-
Global Gene Therapy Partnering Terms and Agreements 2014 to 2019
... the worlds leading healthcare companies. Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapypartnering contract documents Top gene therapy deals by value The Global Gene Therapy ... Read More
-
2019 Global Forecast for Gene Panel (2020-2025 Outlook)-High Tech & Emerging Markets Report
... global market is expected to increase from USD xx billion in 2019 to USD xx billion by 2025, at a CAGR of xx% from 2019 to 2025. Estimates on equipment or material sales (product shipments ... Read More
-
Global Gene Therapy for CNS Disorders Market 2019-2023
... receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a ... Read More
-
Viral Vector Manufacturing - Global Market Outlook (2017-2026)
... growing at a CAGR of 18.0% during the forecast period. The increasing prevalence of target diseases and disorders, a rising number of clinical studies and availability of funding for gene therapy development, and potential applications ... Read More
-
Viral Vector Manufacturing Market - Growth, Trends, and Forecast (2019 - 2024)
... are driving the market include the rising prevalence of genetic disorders, cancer, and infectious diseases, the increasing number of clinical studies, and availability of funding for gene therapy development, and potential applications in novel drug ... Read More
-
United States Gene Therapy Market Report 2018
... only four companies approved by FDA: Kite Pharma, BioVex, Novartis and Spark Therapeutics. The major players in Gene Therapy market include Kite Pharma BioVex Novartis Spark Therapeutics Geographically, this report is segmented into several key ... Read More
-
The 2020-2025 World Outlook for Gene Therapy
... industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge ... Read More
-
Emerging Gene Therapies - Trends within the Technological, Clinical, Regulatory and Competitive Landscape
... last two years have seen the approval of four gene therapies by the FDA - (1) Luxturna, the first in vivo gene transfer therapy (2) Imlygic, an novel immunotherapy, (3) Kymriah and (4) Yescarta, two ... Read More
-
Global Hemoglobinopathies Treatment Market 2019-2023
... global hemoglobinopathies treatment market. Technavio’s analysts have predicted that the hemoglobinopathies treatment market will register a CAGR of almost 11% by 2023. Market Overview Strong pipeline and expected approvals of late-stage molecule The market is ... Read More
-
Cell and Gene Therapy CROs Market, 2018-2030
... more than 25 such advanced therapy medicinal products are available in the market; examples of recently approved therapies include Alofisel® (2018), LUXTURNA™ (2017), YESCARTA™ (2017), Kymriah™ (2017) and INVOSSA™ (2017). In addition, over 500 cell ... Read More
-
Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology and Market Forecast-2027
... United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the ... Read More
-
Transthyretin Amyloidosis (ATTR) - Epidemiology Forecast to 2027
... and United Kingdom), and Japan. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2015-2027 Transthyretin Amyloidosis (ATTR) Epidemiology The Transthyretin Amyloidosis epidemiology division ... Read More
-
Gene Editing and Gene Therapy Breakthroughs Propelling Mainstream Treatments
... Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme replacement therapies, usually prescribed for inherited diseases, to correct the root cause ... Read More
-
Global Gene Therapy Market 2018-2022
... and cardiovascular. It is the usage of modified gene injected into the patient’s body primarily through virus as a vector. This transmitted gene reaches the intended site to kill or treat the infected cell, thus ... Read More
-
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018
... (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018 Summary Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Prot Read More
-
Duchenne Muscular Dystrophy: KOL Insight [2018]
... known cure and few treatment options. Since 2014, two antisense oligonucleotide therapies [Exondys 51 (Sarepta Therapeutics) and Translarna (PTC Therapeutics)] have been approved but how are they faring on the market? Find out how key ... Read More
-
Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing
... antigen receptor T-cells, or CAR T-cells) or RNA therapy platforms. Delivery technologies covered include AAV, adenovirus, lentivirus, retrovirus, other viral and nonviral. Disease areas covered include cardiology, oncology, ophthalmology, hematology, musculoskeletal, neurology, rare diseases and ... Read More
-
Growth Insights for the Direct-to-Consumer Genetic Testing Market, Forecast to 2022
... genetic test (DTCGT) exemplifies this trend which can be purchased and used directly by consumers without the requirement of a prescription from a healthcare provider. The tests can be purchased online from distribution channels such ... Read More
-
Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023
... manufacturing market is projected to grow at a CAGR of 20.0%.” The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a ... Read More
-
Gene Therapy in CVMD
... stages, gene therapy aims to treat or alleviate a disease by genetically modifying the cells of a patient. This report focuses on gene therapies in development across the 8MM for cardiovascular and metabolic disorders, including ... Read More
